celecoxib and Papilloma, Squamous Cell studies

Research Excerpts

Excerpt	Relevance	Reference
"Recurrent respiratory papillomas, caused by human papillomaviruses, are premalignant tumors that overexpress the epidermal growth factor receptor (EGFR)."	7.73	Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. ( Abramson, AL; Dannenberg, AJ; Shikowitz, MJ; Steinberg, BM; Wu, R, 2005)
"Recurrent respiratory papillomas, caused by human papillomaviruses, are premalignant tumors that overexpress the epidermal growth factor receptor (EGFR)."	3.73	Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. ( Abramson, AL; Dannenberg, AJ; Shikowitz, MJ; Steinberg, BM; Wu, R, 2005)
"Despite 3 years of treatment, the papillomatosis proved difficult to control, requiring a procedure approximately every 3 months."	1.51	Squamous Cell Papillomatosis in the Setting of Recurrent Respiratory Papillomatosis. ( Bentley, PL; Coulter, MJ; Nelson, BL, 2019)
"The ratios of squamous cell carcinomas to papillomas and of sebaceous gland adenomas to papillomas plus squamous cell carcinomas were increased markedly in transgenic mice treated with DMBA alone compared with DMBA/phorbol 12-myristate 13-acetate-treated transgenic and wild-type mice."	1.31	Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. ( Berger, I; Furstenberger, G; Marks, F; Muller-Decker, K; Neufang, G; Neumann, M, 2002)

Research

Studies (6)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Correlation Between Mean Plasma Level of Celecoxib and Response.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (66.67)	29.6817
2010's	2 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Bentley, PL	1
Coulter, MJ	1
Nelson, BL	1
Limsukon, A	1
Susanto, I	1
Soo Hoo, GW	1
Dubinett, SM	1
Batra, RK	1
Rosenthal, DW	1
DeVoti, JA	1
Steinberg, BM	2
Abramson, AL	2
Bonagura, VR	1
Muller-Decker, K	1
Neufang, G	1
Berger, I	1
Neumann, M	1
Marks, F	1
Furstenberger, G	1
Won, YK	1
Ong, CN	1
Shi, X	1
Shen, HM	1
Wu, R	1
Shikowitz, MJ	1
Dannenberg, AJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis[NCT00571701]	Phase 2	50 participants (Actual)	Interventional	2008-02-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Mean plasma levels of celecoxib over months 3-12 in first treatment period correlated with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months

Effect of Gender on Percent of Patients With Reduction in Papilloma Growth Rate Greater Than 50%.

Intervention	pg. celecoxib/ml. plasma (Mean)
Responders	151.3
Non-responders	543.41

Percent of patients of each gender with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline (NCT00571701)
Timeframe: Baseline to12 months

Effect of HPV 6 Versus HPV 11 on Percent of Patients With Reduction in Papilloma Growth Rate Greater Than 50%

Intervention	percent responders (Number)
Celecoxib First - Males	12.50
Placebo First- Males	40.00
Celecoxib First- Females	12.50
Placebo First- Females	0.00

Percent of patients with HPV 6 versus patients with HPV 11 with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months

Effect of Juvenile Versus Adult Disease Onset on Percent of Patients With Reduction in Papilloma Growth Rate Greater Than 50%.

Intervention	percent of responders (Number)
Celecoxib First - HPV 6	9.09
Placebo First- HPV 6	42.86
Celecoxib First- HPV 11	25.00
Placebo First- HPV 11	0.00

Percent of juvenile versus adult onset patients with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months

Maintenance of Response Following Discontinuation of Celecoxib

Intervention	percentage of responders (Number)
Celecoxib First- Juvenile Onset	12.50
Placebo First- Juvenile-onsent	7.69
Celecoxib First - Adult Onset	12.50
Placebo First- Adult-onset	33.33

Percent of patients who responded to celecoxib with increase in papilloma growth rate of no greater than 0.01 at end of second treatment period compared to growth rate at end of first treatment period. (NCT00571701)
Timeframe: End of first treatment period (month 12) to end of second treatment period (month 24)

Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline

Intervention	percent of patients (Number)
Celecoxib Responders-maintained	100

Change in mean growth rates during the last 3 months of the first treatment period compared to the mean values at baseline. Endoscopy and removal of all tumor was done every 3 months. Growth rate is calculated as the scored amount of papilloma recurrence in a 3 month period divided by the exact number of days since last endoscopy and removal of all tumor. (NCT00571701)
Timeframe: Baseline to 12 months

Percent of Patients With Positive Response to Treatment

Intervention	percent change in mean growth rate (Mean)
Celecoxib First, Then Placebo	-5.4
Placebo First, Then Celecoxib	-15.2

Percent of patients with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline (NCT00571701)
Timeframe: Baseline to 12 months

Article	Year
Squamous Cell Papillomatosis in the Setting of Recurrent Respiratory Papillomatosis. Head and neck pathology, 2019, Volume: 13, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Human Papillomavirus Recombinant Vaccine Quadriv	2019
Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. Chest, 2009, Volume: 136, Issue:3 Topics: Biopsy; Bronchoscopy; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Erlotinib Hyd	2009
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2002, Sep-17, Volume: 99, Issue:19 Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenoma; Animals; Carcinogens; Carcinoma, Squamous Cell; Celecoxib	2002
Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis, 2004, Volume: 25, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Blotting, West	2004
Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Apoptosis; Blotting, Western; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cycl	2005

Intervention	percent responders (Number)
Celecoxib First (12 Months), Then Placebo (12 Months)	12.5
Placebo First (12 Months), Then Celecoxib (12 Months)	28.6

celecoxib and Papilloma, Squamous Cell